Literature DB >> 30310466

Nicorandil and Long-acting Nitrates: Vasodilator Therapies for the Management of Chronic Stable Angina Pectoris.

Jason M Tarkin1,2, Juan Carlos Kaski3.   

Abstract

Nicorandil and long-acting nitrates are vasodilatory drugs used commonly in the management of chronic stable angina pectoris. Both nicorandil and long-acting nitrates exert anti-angina properties via activation of nitric oxide (NO) signalling pathways, triggering vascular smooth muscle cell relaxation. Nicorandil has additional actions as an arterial K+ ATP channel agonist, resulting in more "balanced" arterial and venous vasodilatation than nitrates. Ultimately, these drugs prevent angina symptoms through reductions in preload and diastolic wall tension and, to a lesser extent, epicardial coronary artery dilatation and lowering of systemic blood pressure. While there is some evidence to suggest a modest reduction in cardiovascular events among patients with stable angina treated with nicorandil compared to placebo, this prognostic benefit has yet to be proven conclusively. In contrast, there is emerging evidence to suggest that chronic use of long-acting nitrates might cause endothelial dysfunction and increased cardiovascular risk in some patients.

Entities:  

Keywords:  Nicorandil; coronary artery disease; long-acting nitrates; stable angina; vasodilators

Year:  2018        PMID: 30310466      PMCID: PMC6159464          DOI: 10.15420/ecr.2018.9.2

Source DB:  PubMed          Journal:  Eur Cardiol        ISSN: 1758-3756


  81 in total

1.  Attenuation of anti-ischemic efficacy during chronic therapy with nicorandil in patients with stable angina pectoris.

Authors:  R Rajaratnam; D B Brieger; R Hawkins; S B Freedman
Journal:  Am J Cardiol       Date:  1999-04-01       Impact factor: 2.778

2.  Impact of nicorandil in angina: subgroup analyses.

Authors: 
Journal:  Heart       Date:  2004-12       Impact factor: 5.994

3.  Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin.

Authors:  J D Parker; B Farrell; T Fenton; M Cohanim; J O Parker
Journal:  Circulation       Date:  1991-12       Impact factor: 29.690

Review 4.  A potassium channel opener as monotherapy in chronic stable angina pectoris: comparison with placebo.

Authors:  H J Why; P J Richardson
Journal:  Eur Heart J       Date:  1993-07       Impact factor: 29.983

Review 5.  Side effects of using nitrates to treat angina.

Authors:  Udho Thadani; Tiffany Rodgers
Journal:  Expert Opin Drug Saf       Date:  2006-09       Impact factor: 4.250

6.  Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial.

Authors: 
Journal:  Lancet       Date:  2002-04-13       Impact factor: 79.321

7.  Comparison of nicorandil and atenolol in stable angina pectoris.

Authors:  L O Hughes; E L Rose; A Lahiri; E B Raftery
Journal:  Am J Cardiol       Date:  1990-09-15       Impact factor: 2.778

8.  Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients.

Authors:  G Döring
Journal:  J Cardiovasc Pharmacol       Date:  1992       Impact factor: 3.105

9.  Vasodilatory effect of nicorandil on coronary arterial microvessels: its dependency on vessel size and the involvement of the ATP-sensitive potassium channels.

Authors:  K Akai; Y Wang; K Sato; N Sekiguchi; A Sugimura; T Kumagai; T Komaru; H Kanatsuka; K Shirato
Journal:  J Cardiovasc Pharmacol       Date:  1995-10       Impact factor: 3.105

10.  Effects of nicorandil on exercise tolerance in patients with stable effort angina: a double-blind study.

Authors:  N Hayata; H Araki; M Nakamura
Journal:  Am Heart J       Date:  1986-12       Impact factor: 4.749

View more
  16 in total

Review 1.  Relief of Ischemia in Ischemic Cardiomyopathy.

Authors:  Francesco Moroni; Zachary Gertz; Lorenzo Azzalini
Journal:  Curr Cardiol Rep       Date:  2021-06-03       Impact factor: 2.931

Review 2.  Pathobiology and evolving therapies of coronary artery vasospasm.

Authors:  Monish A Sheth; Robert J Widmer; Hari K Dandapantula
Journal:  Proc (Bayl Univ Med Cent)       Date:  2021-04-21

Review 3.  The Diverse Biological Activity of Recently Synthesized Nitro Compounds.

Authors:  Saúl Noriega; Jaime Cardoso-Ortiz; Argelia López-Luna; Ma Del Refugio Cuevas-Flores; Juan Armando Flores De La Torre
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-05

4.  Assessment of the Efficacy and Safety of Early Intracoronary Nicorandil Administration in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

Authors:  Himanshu Gupta; Shishirendu Parihar; V D Tripathi
Journal:  Cureus       Date:  2022-05-26

Review 5.  Aging-Induced Impairment of Vascular Function: Mitochondrial Redox Contributions and Physiological/Clinical Implications.

Authors:  Evan Paul Tracy; William Hughes; Jason E Beare; Gabrielle Rowe; Andreas Beyer; Amanda Jo LeBlanc
Journal:  Antioxid Redox Signal       Date:  2021-09-17       Impact factor: 7.468

Review 6.  Nicorandil prior to primary percutaneous coronary intervention improves clinical outcomes in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials.

Authors:  Li Xu; Lefeng Wang; Kuibao Li; Zhiyong Zhang; Hao Sun; Xinchun Yang
Journal:  Drug Des Devel Ther       Date:  2019-04-29       Impact factor: 4.162

Review 7.  A pathophysiological compass to personalize antianginal drug treatment.

Authors:  Edoardo Bertero; Gerd Heusch; Thomas Münzel; Christoph Maack
Journal:  Nat Rev Cardiol       Date:  2021-07-07       Impact factor: 32.419

8.  Enabling patient-reported outcome measures in clinical trials, exemplified by cardiovascular trials.

Authors:  Theresa M Coles; Adrian F Hernandez; Bryce B Reeve; Karon Cook; Michael C Edwards; Marc Boutin; Elizabeth Bush; Arnold Degboe; Lothar Roessig; Amy Rudolph; Pauline McNulty; Nikunj Patel; Trish Kay-Mugford; Margaret Vernon; Michael Woloschak; Gustavo Buchele; John A Spertus; Matthew T Roe; Denise Bury; Kevin Weinfurt
Journal:  Health Qual Life Outcomes       Date:  2021-06-13       Impact factor: 3.186

9.  Efficacy and Safety of Nicorandil in Preventing Contrast-Induced Nephropathy after Elective Percutaneous Coronary Intervention: A Pooled Analysis of 1229 Patients.

Authors:  Bin Yi; Shaoyan Mo; Yumei Jiang; Dingwu Yi; Jinwen Luo; Xiang Chen; Jian Rong
Journal:  J Interv Cardiol       Date:  2020-09-04       Impact factor: 2.279

Review 10.  Protective Effect of Nicorandil on Cardiac Microvascular Injury: Role of Mitochondrial Integrity.

Authors:  Xiaosi Jiang; Dan Wu; Zichao Jiang; Weiwei Ling; Geng Qian
Journal:  Oxid Med Cell Longev       Date:  2021-07-03       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.